Estimate (LOR) | SE | t value | P value | 95% CI | |
Crude model 51 studies (k=104) | |||||
Main effects | |||||
Intercept | −0.35 | 0.05 | −6.8 | <0.0001 | −0.46 to −0.25 |
Female (%) | 0.06 | 0.18 | 0.34 | 0.7335 | −0.30 to 0.43 |
Age | −0.06 | 0.07 | −0.89 | 0.3733 | −0.19 to 0.07 |
Design | −0.17 | 0.06 | −2.82 | 0.0059 | −0.28 to −0.05 |
Follow-up | 0.004 | 0.008 | 0.53 | 0.5965 | −0.012 to 0.02 |
Exposure dose | −0.019 | 0.002 | −8.6 | <0.0001 | −0.02 to −0.14 |
Depression measure | 0.07 | 0.12 | 0.57 | 0.5707 | −0.17 to 0.31 |
Physical activity measure | −0.18 | 0.04 | −4.2 | <0.0001 | −0.27 to −0.10 |
Physical activity domain | −0.09 | 0.13 | −0.70 | 0.4876 | −0.34 to 0.16 |
Study quality | 0.006 | 0.07 | 0.82 | 0.9352 | −0.14 to 0.15 |
Adjusted model 91 studies (k=179) | |||||
Intercept | −0.26 | 0.022 | −11.9 | <0.0001 | −0.31 to −0.22 |
Female (%) | −0.011 | 0.04 | −0.26 | 0.7986 | −0.10 to 0.08 |
Age | 0.009 | 0.026 | 0.36 | 0.7212 | −0.04 to 0.06 |
Design | −0.17 | 0.05 | −3.8 | 0.0002 | −0.26 to −0.08 |
Follow-up | −0.002 | 0.004 | −0.60 | 0.5552 | −0.01 to 0.005 |
Exposure dose | −0.08 | 0.007 | −11.2 | <0.0001 | −0.09 to −0.06 |
Depression measure | −0.05 | 0.05 | −0.99 | 0.3250 | −0.14 to 0.05 |
Physical activity measure | 0.017 | 0.05 | 0.35 | 0.7291 | −0.08 to 0.11 |
Physical activity domain | −0.09 | 0.06 | −1.57 | 0.1192 | −0.20 to 0.024 |
Study quality | −0.032 | 0.036 | −0.88 | 0.3805 | −0.10 to 0.040 |
Adjustments | −0.012 | 0.032 | −0.38 | 0.7062 | −0.07 to 0.05 |
K, number of effects; LOR, log odds ratio.